ClinicalTrials.gg
CompletedNCT00219284Updated Mar 30, 2017Results posted

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

A Phase 4 interventional study of Carbidopa/levodopa/entacapone in Parkinson's Disease With End of Dose Wearing Off, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 2 countries. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-03-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.

Enrollment
3rd of 24
359 · median 46
Started
2005
with 2 others
Phase 4
9 of 24
1 open now
Registered
2nd of 24
by date
Lead sponsor
3 of 24
Novartis Pharmaceuticals

Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2005, is one of 9 in phase 4, and was the 2nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carbidopa

Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing carbidopa in Parkinson Disease, or all of them as a file.
02

Study summary

To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.

Read the detailed description

This was a prospective, multi-center, randomized, open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to carbidopa/levodopa/entacapone on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.

03

Conditions studied

  • Parkinson's Disease With End of Dose Wearing Off

Keywords

  • Parkinson's disease, tremor
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 30-80 years of age (inclusive). Patients aged 81-85 years were eligible to participate if the principal investigator considered the patient to be in otherwise good health.
  • Clinical diagnosis of Parkinson's disease exhibiting two of three symptoms (rigidity, resting tremor, bradykinesia).
  • All patients were required to have end-of dose wearing off (EODWO, re-emergence of PD symptoms at the end of at least two daily doses of levodopa during waking hours).
  • Taking regular doses of immediate release carbidopa/levodopa

Exclusion criteria

Exclusion Criteria:

  • Unstable Parkinson's Disease requiring booster doses or treatment with as needed dose regimens of levodopa
  • Female subjects who are pregnant, trying to become pregnant or nursing an infant

Other protocol-defined inclusion/exclusion criteria applied to this study.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Immediate switch

    Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.

    Drug: Carbidopa/levodopa/entacapone

  • Active comparator
    Delayed switch

    Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.

    Drug: Carbidopa/levodopa/entacapone

Interventions

  • DrugCarbidopa/levodopa/entacapone

    Drug pages: Carbidopa · Levodopa · Entacapone

    Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.

06

What researchers measure

Primary outcomes

  1. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4

    Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4

    Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

    Time frame: Baseline to Week 4

  2. Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8

    Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

    Time frame: Baseline to Week 8

  3. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8

    Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5-point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: Baseline to Week 8

  4. Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4

    The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

    Time frame: Baseline to Week 4

  5. Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8

    The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

    Time frame: Baseline to Week 8

  6. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment

    Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)

  7. Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment

    Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

    Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)

  8. Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment

    The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

    Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)

07

Results

Posted Mar 15, 2011

Participant flow

Treatment Phase - 16 Weeks
Participant flow — Treatment Phase - 16 Weeks
MilestoneImmediate SwitchDelayed Switch
Started180179
Completed136128
Not completed4451
Withdrew: Adverse event2624
Withdrew: Abnormal laboratory value(s)01
Withdrew: Lack of efficacy310
Withdrew: Protocol violation95
Withdrew: Withdrawal by subject59
Withdrew: Lost to follow-up12
Extension Phase - 8 Weeks
Participant flow — Extension Phase - 8 Weeks
MilestoneImmediate SwitchDelayed Switch
Started114106
Completed11299
Not completed27
Withdrew: Adverse event23
Withdrew: Withdrawal by subject02
Withdrew: Lost to follow-up02

Outcome measures

PrimaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4

Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Units on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4
Units on a scaleImmediate SwitchDelayed Switch
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4-3.7 ± 0.66-1.8 ± 0.58
SecondaryChange in Parkinson's Disease Quality of Life Score From Baseline to Week 4

Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Units on a scale
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4
Units on a scaleImmediate SwitchDelayed Switch
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4-0.4 ± 0.881.1 ± 0.77
SecondaryChange in Parkinson's Disease Quality of Life Score From Baseline to Week 8

Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8
Units on a scaleImmediate SwitchDelayed Switch
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8-2.5 ± 1.01-1.1 ± 0.89
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8

Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5-point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8
Units on a scaleImmediate SwitchDelayed Switch
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8-3.6 ± 0.71-3.7 ± 0.62
SecondaryChange in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4

The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · Units on a scale
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4
Units on a scaleImmediate SwitchDelayed Switch
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4-1.7 ± 1.340.8 ± 1.17
SecondaryChange in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8

The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8
Units on a scaleImmediate SwitchDelayed Switch
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8-5.8 ± 1.48-1.9 ± 1.31
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment

Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
Reported as:
Least squares mean · Units on a scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment
Units on a scaleImmediate SwitchDelayed Switch
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment-3.6 ± 0.69-3.3 ± 0.64
SecondaryChange in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment

Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.

Time frame:
Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
Reported as:
Least squares mean · Units on a scale
Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment
Units on a scaleImmediate SwitchDelayed Switch
Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment-1.3 ± 0.970.2 ± 0.89
SecondaryChange in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment

The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.

Time frame:
Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
Reported as:
Least squares mean · Units on a scale
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment
Units on a scaleImmediate SwitchDelayed Switch
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment-2.8 ± 1.600.4 ± 1.47

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Switch—8/180 (4.4%)100/180 (55.6%)
Delayed Switch—12/179 (6.7%)66/179 (36.9%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventImmediate SwitchDelayed Switch
Cardiac failure congestiveCardiac disorders0/1802/179
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1802/179
Atrial fibrillationCardiac disorders0/1801/179
Myocardial infarctionCardiac disorders0/1801/179
DiarrhoeaGastrointestinal disorders1/1801/179
Pancreatitis acuteGastrointestinal disorders0/1801/179
VomitingGastrointestinal disorders0/1801/179
AbscessInfections and infestations0/1801/179
BronchitisInfections and infestations0/1801/179
Viral infectionInfections and infestations0/1801/179
Most frequent other events
Most frequent other events
EventImmediate SwitchDelayed Switch
NauseaGastrointestinal disorders31/18013/179
DiarrhoeaGastrointestinal disorders29/18021/179
DizzinessNervous system disorders16/18013/179
DyskinesiaNervous system disorders7/18012/179
FatigueGeneral disorders12/1806/179
ChromaturiaRenal and urinary disorders12/18010/179
ConstipationGastrointestinal disorders10/1806/179
Pain in extremityMusculoskeletal and connective tissue disorders9/1803/179
TremorNervous system disorders9/1806/179
DepressionPsychiatric disorders9/1807/179

Baseline characteristics

Age, Continuous
Age, Continuous(years)Immediate SwitchDelayed SwitchTotal
Mean68.7 ± 9.1868.3 ± 10.3868.5 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Immediate SwitchDelayed SwitchTotal
Female7471145
Male106108214
08

Study locations

42 sites
  • Phoenix, Arizona 85006, United States
  • Fullerton, California 92835, United States
  • Irvine, California 92618, United States
  • La Jolla, California 92037, United States
  • Los Angeles, California 90033, United States
  • Pasadena, California 91105, United States
  • Reseda, California 91355, United States
  • Stanford, California 94305, United States
  • Ft. Collins, Colorado 80524, United States
  • Washington DC, District of Columbia 20007, United States
  • Boca Raton, Florida 33486, United States
  • Bradenton, Florida 34205, United States
  • Fort Lauderdale, Florida 33308, United States
  • Hollywood, Florida 33021, United States
  • Naples, Florida 34102, United States
  • Palm Beach, Florida 33418, United States
  • Plantation, Florida 33324, United States
  • Pompano Beach, Florida 33060, United States
  • Port Charlotte, Florida 33952, United States
  • Chicago, Illinois 60637, United States
  • Flossmoor, Illinois 60402, United States
  • Lenexa, Kansas 66214, United States
  • Topeka, Kansas 66606, United States
  • Baltimore, Maryland 21201, United States
  • Bingham Farms, Michigan 48025, United States
  • Southfield, Michigan 48034, United States
  • Hattiesburg, Mississippi 39401, United States
  • Columbia, Missouri 65201, United States
  • St. Louis, Missouri 63141, United States
  • Ridgewood, New Jersey 07450, United States
  • Commack, New York 11725, United States
  • Durham, North Carolina 27705, United States
  • Raleigh, North Carolina 27607, United States
  • Bellevue, Ohio 44811, United States
  • Canton, Ohio 44718, United States
  • Tualatin, Oregon 97602, United States
  • East Stroudsburg, Pennsylvania 18301, United States
  • Houston, Texas 77030, United States
  • Spokane, Washington 99204, United States
  • Tacoma, Washington 98405, United States
  • Milwaukee, Wisconsin 53233, United States
  • Caroline, 00983, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Sep 22, 2005
Start
Jan 2005
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Mar 15, 2011
Last update
Mar 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00219284
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Jan 2005
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Mar 15, 2011
Last update
Mar 30, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone

Start the discussion